石基信息(002153.SZ):思迅軟件申請北交所上市並獲受理
格隆匯3月31日丨石基信息(002153.SZ)公佈,公司通過全資子公司中長石基信息技術(海南)有限公司(“石基海南”)持有深圳市思迅軟件股份有限公司(“思迅軟件”,證券代碼:838758)66.23%的股份,思迅軟件系公司控股子公司。
根據思迅軟件吿知,近日思迅軟件已向北京證券交易所(“北交所”)報送了向不特定合格投資者公開發行股票並上市的申報材料。2023年3月31日,思迅軟件收到北交所出具的《受理通知書》(GF2023030004),北交所已正式受理思迅軟件向不特定合格投資者公開發行股票並在北交所上市的申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.